Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
The ground-breaking project, led by Genomics England and NHS England, was established in 2013 to sequence 100,000 whole genomes from NHS patients and their families
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
The medicine is now approved for eight indications across five different types of cancer in China.
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The aim is to create new genomics solutions that could combat cancer and advance market access
Subscribe To Our Newsletter & Stay Updated
